Stevanato Group S.p.A. (STVN) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $14.77. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of STVN = $30.74 (+108.1% from the current price, the stock appears undervalued). Analyst consensus target is STVN = $25 (+65.9% upside).
Valuation: STVN trades at a trailing Price-to-Earnings (P/E) of 22.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.05.
Financials: revenue is $1.1B, +5.1%/yr average growth. Net income is $134M, growing at -1.1%/yr. Net profit margin is 11.8% (healthy). Gross margin is 29% (-3.5 pp trend).
Balance sheet: total debt is $471M against $1.5B equity (Debt-to-Equity (D/E) ratio 0.32, conservative). Current ratio is 1.74 (strong liquidity). Debt-to-assets is 18.5%. Total assets: $2.5B.
Analyst outlook: 5 / 8 analysts rate STVN as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 85/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 44/100 (Fail), Future 73/100 (Pass), Income 55/100 (Partial).
